No photo of Ben Markman

View Scopus Profile

Ben Markman

Dr

20082024
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2024

A Phase 1b, Open-Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety , Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination with the PARP Inhibitor BGB-290 in Subjects with Advanced Solid Tumors

Markman, B.

25/03/19 → 24/03/24

Project: Research

Modulation Of the Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise with PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Markman, B.

8/03/19 → 7/03/24

Project: Research

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects with Advanced Solid Tumors

Markman, B.

28/02/19 → 27/02/24

Project: Research

A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD 73 Antibody, CP-I006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Markman, B.

12/02/19 → 11/02/24

Project: Other

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Cancers

Markman, B.

29/01/19 → 28/01/24

Project: Research

Research Output 2008 2018

A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

Alamgeer, M., Neil Watkins, D., Banakh, I., Kumar, B., Gough, D. J., Markman, B. & Ganju, V., 1 Apr 2018, In : Investigational New Drugs. 36, 2, p. 288-298 11 p.

Research output: Contribution to journal › Article › Research › peer-review

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L. & Hughes, B. G. M., 1 Feb 2018, In : Targeted Oncology. 13, 1, p. 89-98 10 p.

Research output: Contribution to journal › Article › Research › peer-review

mTOR inhibition beyond rapalogs

Markman, B., Serra, V. & Tabernero, J., 2016, mTOR Inhibition for Cancer Therapy: Past, Present and Future. Mita, M., Mita, A. & Rowinsky, E. K. (eds.). Paris France: Springer, p. 251 - 27 25 p.

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Research › peer-review

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors

Papadopoulos, K. P., Tabernero, J., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J., Shi, W., Egile, C., Ruiz-Soto, R., Laird, A. D., Miles, D. & LoRusso, P. M., 2014, In : Clinical Cancer Research. 20, 9, p. 2445 - 2456 12 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access

PI3K pathway inhibitors: better not left alone

Markman, B., Tao, J. J. & Scaltriti, M., 2013, In : Current Pharmaceutical Design. 19, 5, p. 895 - 906 12 p.

Research output: Contribution to journal › Article › Research › peer-review